Aptamer Sciences Inc (KOSDAQ: 291650)

Market Cap	31.75B
Revenue (ttm)	216.07M
Net Income (ttm)	-13.48B
Shares Out	16.98M
EPS (ttm)	-793.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	331,875
Open	2,235.00
Previous Close	2,175.00
Day's Range	2,045.00 - 2,235.00
52-Week Range	1,950.00 - 4,875.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Aptamer Sciences

Aptamer Sciences, Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s aptamer platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics. It offers AlloMAp and BiFAp platform programs for therapeutics; and diagnosis kits for lung and pancreatic cancer, as well as in-vitro diagnostic kits for the early diagnosis of lung cancer. Aptamer Sciences, Inc. was founded in 2011 and is headquartered in Seongnam, South...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 291650

Financial Performance

In 2023, Aptamer Sciences's revenue was 243.19 million, a decrease of -32.12% compared to the previous year's 358.25 million. Losses were -13.60 billion, 91.2% more than in 2022.